Diagnostic-therapeutic pathway and organizational model for gene therapy in the administration of congenital retinal dystrophies in real-life
DOI:
https://doi.org/10.33393/ao.2023.2565Keywords:
Congenital retinal dystrophies, Diagnostic-therapeutic pathway, Gene therapy, Leber congenital amaurosis, Value framework, Voretigene neparvovecAbstract
Background: Leber congenital amaurosis is the first form of inherited retinal dystrophy (IRD) treated with a gene therapy approach using voretigene neparvovec (VN). To date, 42 patients have been treated, 25 of whom, treated at Clinica Oculistica Vanvitelli (Naples), have shown – after 45 days of treatment – a significant increase in dim-light visual function, a widening of the visual field, and an increase in central visual acuity.
Objective: A workshop has been organized to foster rapid access, investigate the current organizational scenario, and identify a value framework suitable for making gene therapy delivery efficient in terms of efficacy, safety, and sustainability.
Methods: The workshop involved 14 experts in clinical genetics, ophthalmology, and vitreoretinal surgery. All experts were subjected to questions related to three topics: diagnostic-therapeutic pathway of IRD patients, essential requirements for gene therapy delivery centres, and standardized model for therapy delivery. All contributions were judged to be of equal value.
Results: The panel identified: the steps of the diagnostic pathway to achieve early diagnosis; the essential criteria that delivery centres must possess in terms of experience, multidisciplinary team, and technical equipment; a standardized model for VN administration.
A network of few centres was identified as the best organizational model for VN delivery since it would ensure the gaining of experience and clinical excellence.
Conclusion: This paper provides a perspective that can be used as a starting point to standardize the diagnostic-therapeutic pathway of IRD patients and define the essential requirements that centres must meet for VN administration.
References
- Testa F, Murro V, Signorini S, et al. RPE65-Associated Retinopathies in the Italian Population: A Longitudinal Natural History Study. Invest Ophthalmol Vis Sci. 2022;63(2):13. https://doi.org/10.1167/iovs.63.2.13 PMID:35129589 DOI: https://doi.org/10.1167/iovs.63.2.13
- Stone EM. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 2007;144(6):791-811. https://doi.org/10.1016/j.ajo.2007.08.022 PMID:17964524 DOI: https://doi.org/10.1016/j.ajo.2007.08.022
- Amaurosi congenita di Leber, Fondazione Telethon, 2020. Online: https://www.telethon.it/cosa-facciamo/ricerca/malattie-studiate/amaurosi-congenita-di-leber (Accessed January 2023)
- L’Amaurosi congenita di Leber, Associazione Italiana Amaurosi Congenita di Leber, 2003. Online http://www.ialca.org/pubblicazioni_scientifiche/l_amaurosi_congenita_di_leber.php (Accessed January 2023).
- Testa F, Melillo P, Di Iorio V, et al. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. Sci Rep. 2022;12(1):17637. https://doi.org/10.1038/s41598-022-22180-6 PMID:36271235 DOI: https://doi.org/10.1038/s41598-022-22180-6
- Testa F, Melillo P, Della Corte M, et al. Voretigene Neparvovec Gene Therapy in Clinical Practice: Treatment of the First Two Italian Pediatric Patients. Transl Vis Sci Technol. 2021;10(10):11. https://doi.org/10.1167/tvst.10.10.11 PMID:34554209 DOI: https://doi.org/10.1167/tvst.10.10.11
- Sodi A, Banfi S, Testa F, et al; Italian IRD Working Group. RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy. Orphanet J Rare Dis. 2021;16(1):257. https://doi.org/10.1186/s13023-021-01868-4 PMID:34088339 DOI: https://doi.org/10.1186/s13023-021-01868-4